Vitiligo is an acquired disease which occurs in the setting of melanocyte damage (Farnaq et al., 2002). Vitiligo is a systemic disease which presents with spots and patches that lack pigmented cells (Bleechen et al., 1998). This disease is resistant to treatment and consist of relapse and spontaneous recovery (James et al., 2000). The incidence of vitiligo is similar between men and women. Half...

BACKGROUND Vitiligo is a disorder with profound heterogeneity in its aetio-pathophysiology. Angiotensin converting enzyme (ACE) plays an important role in the physiology of the vasculature, blood pressure and inflammation. An insertion/deletion (I/D) polymorphism of the ACE gene was reported be associated with the development of vitiligo. OBJECTIVE Our aim was to evaluate the ACE I/D polymorp...

Background: Vitiligo is an acquired idiopathic disease that appears as skin depigmented patches due to a loss of melanocytes are responsible for producing melanin pigment in the skin, hair, mucous membranes and retina. Objective: To evaluate efficacy topical piperine oil combined with excimer light phototherapy treatment non-segmental vitiligo: comparative intra individual study. Patients metho...

Background: Vitiligo is a chronic cutaneous disease characterized by hypo- or depigmented patches that leave psychological impact on the patients. New treatment modalities have been developed to shorten duration of vitiligo with fewer side effects.
 Objective: To evaluate effect low-level laser therapy (LLLT) in stable vitiligo.
 Patients and Methods: The study included 20 patients ov...

BACKGROUND Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate between 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will provide novel therapeutic and prophylactic targets for future approaches to the treatment and prevention of vitiligo. The purposes of this study were evaluating the efficacy o...

Vitiligo is the most common depigmenting disorder, with a prevalence of approximately 0.5% in the world population. Almost half of the patients with vitiligo present before 20 years of age. The two sexes are affected equally, and there are no apparent differences according to skin type or race.1,2 On histology, vitiligo is identified by the loss of epidermal melanocytes with absence of inflamma...

Vitiligo is an important skin disease of childhood, which may lead to deep psychological trauma, resulting in a poor quality of life and low self-esteem. The Authors discuss a short review of the more conventional therapies available for the treatment of vitiligo in children.

Gefitinib is a tyrosine kinase inhibitor that targets and inhibits epidermal growth factor receptors. It was initially used to treat non-small cell lung cancer but has increasingly been used for other solid tumors such as those in the breast, colorectal sites, and head and neck, as in our patient. Vitiligo is an autoimmune disorder that results in the destruction of melanocytes and subsequent s...